The 36-month beta value for IMNM is at 1.77. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IMNM is 50.90M, and currently, shorts hold a 20.96% of that float. The average trading volume for IMNM on November 27, 2024 was 748.88K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
IMNM) stock’s latest price update
Immunome Inc (NASDAQ: IMNM)’s stock price has increased by 15.26 compared to its previous closing price of 11.53. However, the company has seen a 42.44% increase in its stock price over the last five trading sessions. businesswire.com reported 2024-11-27 that BOTHELL, Wash.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome’s management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 4:30 p.m. Eastern time. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at ww.
IMNM’s Market Performance
IMNM’s stock has risen by 42.44% in the past week, with a monthly rise of 8.93% and a quarterly drop of -12.80%. The volatility ratio for the week is 6.87% while the volatility levels for the last 30 days are 7.13% for Immunome Inc The simple moving average for the last 20 days is 15.96% for IMNM stock, with a simple moving average of -15.58% for the last 200 days.
Analysts’ Opinion of IMNM
Many brokerage firms have already submitted their reports for IMNM stocks, with Stephens repeating the rating for IMNM by listing it as a “Overweight.” The predicted price for IMNM in the upcoming period, according to Stephens is $30 based on the research report published on November 08, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see IMNM reach a price target of $27. The rating they have provided for IMNM stocks is “Overweight” according to the report published on May 31st, 2024.
JP Morgan gave a rating of “Overweight” to IMNM, setting the target price at $24 in the report published on April 30th of the current year.
IMNM Trading at 7.48% from the 50-Day Moving Average
After a stumble in the market that brought IMNM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.07% of loss for the given period.
Volatility was left at 7.13%, however, over the last 30 days, the volatility rate increased by 6.87%, as shares surge +9.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.19% lower at present.
During the last 5 trading sessions, IMNM rose by +42.55%, which changed the moving average for the period of 200-days by -40.60% in comparison to the 20-day moving average, which settled at $11.46. In addition, Immunome Inc saw 24.21% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMNM starting from SIEGALL CLAY B, who purchase 66,057 shares at the price of $9.54 back on Nov 21 ’24. After this action, SIEGALL CLAY B now owns 485,693 shares of Immunome Inc, valued at $630,263 using the latest closing price.
SIEGALL CLAY B, the President and CEO of Immunome Inc, purchase 33,943 shares at $9.78 during a trade that took place back on Nov 22 ’24, which means that SIEGALL CLAY B is holding 519,636 shares at $331,918 based on the most recent closing price.
Stock Fundamentals for IMNM
Current profitability levels for the company are sitting at:
- -31.34 for the present operating margin
- 0.88 for the gross margin
The net margin for Immunome Inc stands at -30.15. The total capital return value is set at -1.46. Equity return is now at value -276.36, with -174.46 for asset returns.
Based on Immunome Inc (IMNM), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -34.98. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -1579.52.
Currently, EBITDA for the company is -28.27 million with net debt to EBITDA at 1.28. When we switch over and look at the enterprise to sales, we see a ratio of 65.88. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.17.
Conclusion
In conclusion, Immunome Inc (IMNM) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
